Detailed Narrative
Q2 FY26 Performance Overview and Market Outperformance
Ipca Laboratories delivered a strong Q2 FY26, with its domestic formulation business growing approximately 8%. Despite impacts from GST rate rationalizations in September 2025, the company outpaced the Indian Pharmaceutical Market (IPM), achieving 11.6% growth against the market's 7.8%. This performance led to an improvement in Ipca's MAT September 2025 market share to 2.8% from 2.3% a year ago, while maintaining its 16th rank in the market.
Robust Margin Expansion Driven by Product Mix and Cost Control
The company reported significant margin expansion in Q2 FY26. Standalone EBITDA margin improved by 2.57% to 25.46% from 22.89% in Q2 FY25. Consolidated EBITDA margin also saw a 2.58% improvement, reaching 21.68% from 19.1%. This positive trend was primarily attributed to a 3-4% reduction in material costs and an improving product mix, with chronic businesses now contributing 35% to Ipca's overall revenue, up from 34%.
Strong API Growth Amidst Mixed Export Performance
The API business was a key highlight, demonstrating robust growth of 28% in Q2 FY26, with revenue increasing from INR319 crores to INR408 crores. In contrast, the export formulation business experienced a decline of approximately 9% in Q2 FY26, falling to INR493 crores from INR541 crores in the prior fiscal year's Q2. However, for the first half of FY26, export formulations remained almost flat at INR941 crores compared to INR937 crores in H1 FY25.
Unichem Integration and Synergy Realization
Integration efforts for Unichem are progressing, with 12 product dossiers filed in European and other markets, with approvals anticipated in 1-1.5 years. Management clarified that R&D spend for Unichem would not decrease due to necessary market extension work, but duplication of efforts would be avoided. Unichem's Q2 EBITDA margin was around 11%, with a target to reach 15-20% in 1.5-2 years. Additionally, Unichem successfully reduced its inventory by approximately INR150 crores this quarter.
Increased R&D Investment for Future Pipeline and Biosimilars
Ipca's R&D spend increased to 3.91% of turnover in Q2 FY26 from 2.7% in Q2 FY25. The company plans to maintain R&D spend around 4% for the full year, potentially increasing it to 4.5-4.75% in the next fiscal year. This investment supports a strengthening pipeline, including bioequivalence studies and filings in various markets. Ipca is also initiating biotech R&D for E. coli-based products, signaling a long-term strategic entry into the GLP segment.
Positive Outlook and Guidance for FY26
The company provided a positive outlook, guiding for an overall India growth of 10-11% for FY26. The API business is expected to grow 14-15% for the full year, and generic formulations are projected to grow 8-9% in H2 FY26. Consolidated EBITDA margin is anticipated to improve by approximately 1% in H2 FY26 compared to the 20% guidance, driven by continued product mix improvement and cost efficiencies.